The total number of records retrieved from this search are 6. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_711	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl/6j mice subcutaneously injected with 5.0E+5 B16F10 cells	In-vivo virus concentration1.0E+7 PFU to 1.0E+9 PFU for three weeks	In-vivo toxicityNA	In-vivo result77% survived till 30 days (Reduction in tumor volume to 0.15 cubic centimeter compared to control 0.9 cubic centimeter after 15 days)	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectUp-regulation of IL-12, IL-5, IL-10, TNF-alpha	Clinical trialNA	PMID27412241
IDOV_712	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl/6j mice subcutaneously injected with 2.0E+5 LLC cells	In-vivo virus concentration1.0E+7 PFU to 1.0E+9 PFU for three weeks	In-vivo toxicityNA	In-vivo result80% survived till 40 days (Reduction in tumor volume to 0.3 cubic centimeter compared to control 1.0 cubic centimeter after 20 days)	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-gamma	Clinical trialNA	PMID27412241
IDOV_713	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl/6j mice subcutaneously injected with 5.0E+5 B16F10 cells (vaccinated with cell-based Reovirus vaccine 8–12 weeks prior to day 0)	In-vivo virus concentration1.0E+7 PFU to 1.0E+9 PFU for three weeks	In-vivo toxicityNA	In-vivo result100% survived till 150 days (Reduction in tumor volume to 0.0 cubic centimeter compared to control 1.4 cubic centimeter after 16 days)	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectUp-regulation of IL-12, IL-5, IL-10, TNF-alpha	Clinical trialNA	PMID27412241
IDOV_714	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl/6j mice subcutaneously injected with 2.0E+5 LLC cells (vaccinated with cell-based Reovirus vaccine 8–12 weeks prior to day 0)	In-vivo virus concentration1.0E+7 PFU to 1.0E+9 PFU for three weeks	In-vivo toxicityNA	In-vivo result100% survived till 200 days (Reduction in tumor volume to 0.0 cubic centimeter compared to control 1.3 cubic centimeter after 11 days)	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-gamma	Clinical trialNA	PMID27412241
IDOV_715	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl/6j mice subcutaneously injected with 5.0E+5 B16F10 cells (prior single dose of cell-based reovirus vaccine for the treatment of established tumours)	In-vivo virus concentration2.0E+7 PFU to 1.0E+9 PFU for three weeks	In-vivo toxicityNA	In-vivo result77% survived till 44 days (Reduction in tumor volume to 0.1 cubic centimeter compared to control 1.2 cubic centimeter after 16 days)	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectUp-regulation of IL-12, IL-5, IL-10, TNF-alpha	Clinical trialNA	PMID27412241
IDOV_716	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl/6j mice subcutaneously injected with 2.0E+5 LLC cells (prior single dose of cell-based reovirus vaccine for the treatment of established tumours)	In-vivo virus concentration3.0E+7 PFU to 1.0E+9 PFU for three weeks	In-vivo toxicityNA	In-vivo result60% survived till 52 days (Reduction in tumor volume to 0.14 cubic centimeter compared to control 21 cubic centimeter after 15 days)	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-gamma	Clinical trialNA	PMID27412241